FDA schedules September advisory panel to review Grail's cancer test after trial miss

The FDA announced it will hold an advisory committee meeting in September to examine Grail's multi‑cancer early detection test.

The test recently failed to meet its primary endpoint in a large, randomized trial conducted in the United Kingdom, prompting concerns about its clinical performance.

The meeting will give regulators, experts and stakeholders a chance to discuss the trial results and decide the next steps for potential approval.

The outcome could influence investor sentiment and the broader development of liquid biopsy technologies.